Cargando…

Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer

BACKGROUND: The optimal interval between neoadjuvant therapy and oesophagectomy for oesophageal cancer remains controversial. METHODS: Patients with locally advanced oesophageal squamous cell carcinoma (ESCC) who received neoadjuvant chemoradiotherapy followed by oesophagectomy between June 2017 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Xin, Cheng, Chao, Cheng, Liang, Shang, Qi-Xin, Yang, Yu-Shang, Zeng, Xiao-Xi, Hu, Yang, Chen, Long-Qi, Yuan, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Thoracic Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628481/ https://www.ncbi.nlm.nih.gov/pubmed/36322275 http://dx.doi.org/10.1245/s10434-022-12758-9

Ejemplares similares

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
por: Gebauer, Florian, et al.
Publicado: (2023)

Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
por: Noordman, B. J., et al.
Publicado: (2019)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy
por: La Mendola, Roberta, et al.
Publicado: (2020)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer
por: Laughlin, Brady, et al.
Publicado: (2019)

Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
por: Zhao, Yue, et al.
Publicado: (2016)

Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy
por: Zhou, Yehan, et al.
Publicado: (2023)

Residual lymph node disease and mortality following neoadjuvant chemoradiation and curative esophagectomy for distal esophageal adenocarcinoma
por: Kandilis, Apostolos, et al.
Publicado: (2020)

Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy
por: Hulshoff, J. B., et al.
Publicado: (2015)

The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy
por: Wu, Lei-Lei, et al.
Publicado: (2023)

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer
por: Wittmann, David, et al.
Publicado: (2020)

Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery
por: Reisinger, Kostan W., et al.
Publicado: (2015)

External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
por: Brinkmann, Sebastian, et al.
Publicado: (2019)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

Rad51 Expression Is a Useful Predictive Factor for the Efficacy of Neoadjuvant Chemoradiotherapy in Squamous Cell Carcinoma of the Esophagus
por: Nakanoko, Tomonori, et al.
Publicado: (2013)

Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery
por: Li, Xiaokun, et al.
Publicado: (2022)

Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer
por: Mayanagi, Shuhei, et al.
Publicado: (2017)

The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer—The Impact in Intratumoral Heterogeneity
por: Bettoni, Fabiana, et al.
Publicado: (2019)

Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis
por: Wang, Helena Hong, et al.
Publicado: (2020)

Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy
por: van der Wilk, Berend J., et al.
Publicado: (2023)

High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma
por: Jomrich, Gerd, et al.
Publicado: (2019)

Perioperative discordance in mesothelioma cell type after pleurectomy/decortication—a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
por: Ventura, Luigi, et al.
Publicado: (2023)

Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report
por: Zhang, Mai, et al.
Publicado: (2022)

Clinical outcome of patients after recurrent laryngeal nerve lymph node dissection for oesophageal squamous cell carcinoma
por: Pai, Chu-Pin, et al.
Publicado: (2021)

Intratracheal recurrence of thymoma 7 years after complete resection
por: Fukuyama, Kaoru, et al.
Publicado: (2023)

Place of robotic surgery in completion lobectomy after anatomical segmentectomy
por: Piccoli, Juliette, et al.
Publicado: (2023)

Feasibility of double sleeve lobectomy after neoadjuvant chemotherapy in patients with non-small-cell lung cancer
por: Bao, Yi, et al.
Publicado: (2022)

Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study
por: van Meerten, E, et al.
Publicado: (2006)

Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Left lower lobectomy without pericardial reconstruction in a patient with a congenital pericardium defect
por: Miura, Jun, et al.
Publicado: (2023)

Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer
por: Bitterman, Danielle S., et al.
Publicado: (2015)

Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation
por: Nelson, Bailey, et al.
Publicado: (2022)

Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015)

Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature
por: Wu, Jie, et al.
Publicado: (2022)

Dynamic Changes in Circulating Tumor DNA During Chemoradiation for Locally Advanced Lung Cancer
por: Corradetti, Michael N., et al.
Publicado: (2019)

Lymphatic Node Metastasis Risk Scoring System: A Novel Instrument for Predicting Lymph Node Metastasis After Thymic Epithelial Tumor Resection
por: Cheng, Xinxin, et al.
Publicado: (2021)

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
por: Adenis, Antoine, et al.
Publicado: (2013)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)

Chemoradiation for oesophageal cancer: the choice of treatment modality
por: Kitti, Pauliina M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mgombj050aanj42a5cf12t35er